NASDAQ:DARE - Nasdaq - US23666P2002 - Common Stock - Currency: USD
2.63
-0.03 (-1.13%)
The current stock price of DARE is 2.63 USD. In the past month the price decreased by -0.38%. In the past year, price decreased by -27.55%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 58.53 | 763.34B | ||
JNJ | JOHNSON & JOHNSON | 16.96 | 407.97B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 19.12 | 314.28B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.94 | 228.44B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.27 | 227.39B | ||
MRK | MERCK & CO. INC. | 10.8 | 211.20B | ||
PFE | PFIZER INC | 7.9 | 144.12B | ||
SNY | SANOFI-ADR | 10.95 | 122.07B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.67 | 99.60B | ||
GSK | GSK PLC-SPON ADR | 8.55 | 77.34B | ||
ZTS | ZOETIS INC | 25.39 | 68.04B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 61.08 | 45.79B |
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 21 full-time employees. The company went IPO on 2014-04-10. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
DARE BIOSCIENCE INC
3655 Nobel Dr Ste 260
San Diego CALIFORNIA 92122 US
CEO: Sabrina Martucci Johnson
Employees: 21
Phone: 18589267655
The current stock price of DARE is 2.63 USD. The price decreased by -1.13% in the last trading session.
The exchange symbol of DARE BIOSCIENCE INC is DARE and it is listed on the Nasdaq exchange.
DARE stock is listed on the Nasdaq exchange.
10 analysts have analysed DARE and the average price target is 13.26 USD. This implies a price increase of 404.18% is expected in the next year compared to the current price of 2.63. Check the DARE BIOSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DARE BIOSCIENCE INC (DARE) has a market capitalization of 23.28M USD. This makes DARE a Nano Cap stock.
DARE BIOSCIENCE INC (DARE) currently has 21 employees.
DARE BIOSCIENCE INC (DARE) has a support level at 2.36 and a resistance level at 2.64. Check the full technical report for a detailed analysis of DARE support and resistance levels.
The Revenue of DARE BIOSCIENCE INC (DARE) is expected to grow by 419.65% in the next year. Check the estimates tab for more information on the DARE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
DARE does not pay a dividend.
DARE BIOSCIENCE INC (DARE) will report earnings on 2025-08-11.
DARE BIOSCIENCE INC (DARE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.18).
The outstanding short interest for DARE BIOSCIENCE INC (DARE) is 0.54% of its float. Check the ownership tab for more information on the DARE short interest.
ChartMill assigns a fundamental rating of 3 / 10 to DARE. DARE may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months DARE reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS increased by 95.31% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -9% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to DARE. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -284.95% and a revenue growth 419.65% for DARE